A single low testosterone reading isn’t a diagnosis. I’m on TRT, and here’s how low testosterone is actually diagnosed, what TRT does, and the fertility risk young men miss.
I take a diabetes drug and have never had diabetes. A plain-English map of the type 2 diabetes drugs, and why the best ones now protect your heart and kidneys, not just blood sugar.
The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor. What it costs, how the pill compares to the shots, and who actually needs it.
A cyclospora outbreak just sickened 1,645 people across 34 states, and romaine keeps causing E. coli recalls. Is romaine lettuce safe to eat, and is it even worth it? A hard look, and what I eat instead.
Finding purpose in retirement is the part no one plans for. Why a project beats a blank calendar, what the research on hobbies and mattering shows, and how to start before you retire.
A BMJ analysis of 262 trials crowned tirzepatide the weight-loss king. But the drug with the hard survival and heart-attack data is the one that finished fifth.
The 2025 blood pressure guidelines sound like a shake-up. Here’s what actually changed about who gets medication, and why it barely moved the needle.
A Yale secret-shopper study tried 49 direct-to-consumer GLP-1 sites. 45 wrote a prescription, some in five minutes. What the questionnaire mills skip, and how to spot real care.
Cold plunges get the attention, but the sauna is the one with decades of hard-outcome data. What the evidence actually says, and why I sauna and skip the plunge.
The GLP-1 muscle loss panic scared me into training at 50. It turned out overblown, but the habit stuck. What the evidence actually says about muscle, and why you train after 50.
